http://journals.lww.com/acsm-msse/F...Basic_Science_World_Congress_Poster__.16.aspx
28-day Guanidinoacetic Acid Supplementation Improves Clinical Outcomes In Patients With Chronic Fatigue Syndrome
Sergej M. Ostojic1, Jay R. Hoffman, FACSM2, Marko Stojanovic1, Patrik Drid1. 1University of Novi Sad, Novi Sad, Serbia. 2University of Central Florida, Orlando, FL. (Sponsor: Jay R. Hoffman, FACSM)
(No relationships reported)
Chronic fatigue syndrome (CFS) is a debilitating illness of unknown etiology.
Recent studies have shown that CFS is associated with impaired cellular energetics and low levels of phosphocreatine.
Since guanidinoacetic acid (GAA) acts as a highly bioavailable precursor of creatine it may provide an ideal dietary supplement to facilitate treatment and perhaps prevention of CFS.
PURPOSE:
To examine the effects of four-week oral GAA administration on clinical outcomes in well-defined adult CFS patients.
METHODS:
Twelve patients who fulfilled the 1994 Centers for Disease Control and Prevention criteria for CFS participated in this randomized, placebo-controlled, double-blind, repeated-measure pilot study.
The subjects were allocated in a double-blind design to receive two randomly assigned trials: first group received 2.4 grams per day of oral GAA, while the second group received placebo (cellulose).
Participants were evaluated at baseline, and following 2- and 4-weeks of ingestion.
The primary endpoint of treatment efficacy was the change in the Multidimensional Fatigue Inventory (MFI-20) score assessed at baseline and at 4 weeks.
RESULTS:
GAA intervention significantly decreased MFI-20 score as compared to the placebo (10.9 ± 2.5 vs. 7.4 ± 1.3%; p = 0.02).
Differences were found for health-related quality of life and muscular strength responses between the groups, with GAA treatment resulting in improvement of both variables as compared to the placebo (p < 0.05).
CONCLUSION:
Results indicate that GAA can be used as a novel dietary agent to positively affect clinical outcomes in adult patients with CFS.
This project was supported by the Serbian Ministry of Education, Science and Technological Development (Grant No. 175037). Trial identification: www.clinicaltrials.gov number NCT02213679.